Battelle Memorial Institute

Battelle Memorial Institute's Pacific Northwest National Laboratory Division, operating as Pacific NW National, is a tax-exempt non-profit research organization based in Richland, Washington, that serves as a prime recipient on federal grants and a subcontractor on research and development contracts, delivering mass spectrometry-based bioanalytical services, multi-omics profiling, advanced analytical platforms, and scientific research support to the federal government.

Pacific NW National operates as the Pacific Northwest division of its parent company Battelle Memorial Institute, headquartered in Columbus, Ohio. The division is not classified under an SBA set-aside category and competes full-and-open across federal customer agencies. Its award portfolio encompasses 255 total federal awards (62% prime, 38% sub) with combined potential value of $34.62 billion, representing a shift toward growth in recent years (10 awards in 2022, 42 in 2024, 24 in 2025, 16 in 2026 year-to-date).

Federal customer concentration is heavily weighted toward the Department of Health and Human Services National Institutes of Health, which accounts for the dominant share of recent awards by count. The top four funding agencies by award count include NIH (40 awards), the NIH Office of the Director (21 awards), the NIH National Institute of Environmental Health Sciences (17 awards), the NIH National Institute of Diabetes and Digestive and Kidney Diseases (16 awards), and the NIH National Institute on Aging (16 awards), collectively covering 43% of awards. However, the Department of Energy Office of Science anchors 100% of the combined potential value at $34.61 billion across 9 awards, creating extreme concentration in dollar magnitude. This divergence reflects Pacific NW National's dual character: high-volume NIH grant work in biomedical research and a smaller number of massive DOE infrastructure contracts.

Pacific NW National's prime grant portfolio centers on mass spectrometry and multi-omics research capabilities. Representative NIH projects include a $2.84 million four-year NIGMS Biomedical Research and Research Training award (CFDA 93.859) to develop an ultra-high resolution ion mobility spectrometer platform for metabolomics research (July 2026–June 2030); a $100 thousand NCCIH Trans-NIH Research Support award (CFDA 93.310) for Phase II of the Natural Products Magnetic Resonance Database (June 2026–May 2031); an $802,595 NIDDK Cooperative Agreement (CFDA 93.847) for spatial multi-omics profiling to discover molecular pathways of early Type 1 Diabetes pathogenesis (May 2026–April 2030); a $465,197 NIGMS award for advanced lipidomic profiling technologies with high structural specificity (September 2025–June 2030); a $450,904 NCI Project Grant for a single-cell phosphoproteomics platform to characterize tumor microenvironment heterogeneity (September 2025–August 2028); and a $221,452 NIH Office of the Director award for molecular analysis of white adipose tissue aging using MOTRPAC data (September 2025–August 2026). The division also holds a $2.84 million NCI Cooperative Agreement for a Center for Advanced Multi-Omic Characterization of Cancer, leading the Clinical Proteomic Tumor Analysis Consortium as a proteome characterization center. This portfolio reflects sustained capability in ion mobility mass spectrometry, single-cell and spatial proteomics, targeted lipidomics, cell-free protein expression, bioinformatics, and metabolomics platform development.

In its sub-award role, Pacific NW National performs specialized analytical and research services under prime contractors. Recent subcontract work includes engineering services to Assured Information Security, Inc., on the TENSHU and VALIANT programs (Air Force); neutron detector testing under Fluor Marine Propulsion, LLC's Naval Nuclear Laboratory management contract (December 2023); technical support for organ-on-chip medical countermeasure evaluation under The Charles Stark Draper Laboratory, Inc. (December 2023); and vaccine development support to International Aids Vaccine Initiative Inc., for monovalent filovirus vaccine development (June 2025). The division also served as a sub-recipient on multiple university-led NIH grants, including work on Type 1 Diabetes biomarker discovery with University of Florida and University of Chicago, pulmonary fibrosis organoid multi-omics analysis with UCLA (LungMAP Phase 3 U01), single-cell proteomics of spiral ganglion neurons with University of Nevada, Reno, and multiple PAH risk characterization centers led by Oregon State University.

Service Contract Inventory data (covering federal service contracts above the $150,000 threshold, FY2022–FY2024) shows Pacific NW National reported as a named subcontractor on 5 SCI records across three fiscal years, with FTE deliveries of 65.9 FTEs in FY2022 declining to 44.8 FTEs in FY2024. These figures represent only a partial view of the division's federal services activity; SCI excludes goods, classified contracts, and the vast majority of the division's grant-funded research and development work.

Pacific NW National carries significant recompete exposure: 14 awards with combined potential value of $34.61 billion reach ultimate completion within the next twenty-four months, driven almost entirely by the DOE Office of Science portfolio. The division holds task order authority under four parent vehicles: Indefinite Delivery Contract FA875023D1000 (3 task orders), Agile Cyber 3 (2 task orders), and two single-task-order IDICs with DOD and NASA. The four task-order vehicles provide limited breadth; Pacific NW National's federal work flows predominantly through direct prime grants (especially NIH) and direct prime contracts rather than through established multi-award IDIQs or GWACs accessible to the broader market.